Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
…, C McGuigan, V Jokubaitis, T Spelman… - The Lancet …, 2017 - thelancet.com
Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis
A He, T Spelman, V Jokubaitis, E Havrdova… - JAMA …, 2015 - jamanetwork.com
Importance After multiple sclerosis (MS) relapse while a patient is receiving an injectable
disease-modifying drug, many physicians advocate therapy switch, but the relative …
disease-modifying drug, many physicians advocate therapy switch, but the relative …
Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection
…, J Gall, C Pickett, L Lal, A Mak, TD Spelman… - Jama, 2019 - jamanetwork.com
Importance Emerging evidence suggests that risk of bacterial sexually transmitted infections
(STIs) increases among gay and bisexual men following initiation of HIV preexposure …
(STIs) increases among gay and bisexual men following initiation of HIV preexposure …
Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis
VG Jokubaitis, T Spelman, T Kalincik… - Annals of …, 2016 - Wiley Online Library
Objective To identify predictors of 10‐year Expanded Disability Status Scale (EDSS) change
after treatment initiation in patients with relapse‐onset multiple sclerosis. Methods Using …
after treatment initiation in patients with relapse‐onset multiple sclerosis. Methods Using …
Development of a prognostic nomogram for predicting the probability of nonresponse to total knee arthroplasty 1 year after surgery
MM Dowsey, T Spelman, PFM Choong - The Journal of arthroplasty, 2016 - Elsevier
Background Indications for total knee arthroplasty (TKA) currently depend on clinical judgment.
Up to one fifth of those who undergo primary TKA do not report a clinically meaningful …
Up to one fifth of those who undergo primary TKA do not report a clinically meaningful …
Switch to natalizumab versus fingolimod in active relapsing–remitting multiple sclerosis
T Kalincik, D Horakova, T Spelman… - Annals of …, 2015 - Wiley Online Library
Objective In patients suffering multiple sclerosis activity despite treatment with interferon β
or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. …
or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. …
[HTML][HTML] Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy
…, J Ahlers, MJ Cameron, MZ Smith, T Spelman… - PLoS …, 2014 - journals.plos.org
<p>Human immunodeficiency virus (HIV) persistence in latently infected resting memory
CD4+ T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are …
CD4+ T-cells is the major barrier to HIV cure. Cellular histone deacetylases (HDACs) are …
Predictors and dynamics of postpartum relapses in women with multiple sclerosis
SE Hughes, T Spelman, OM Gray… - Multiple Sclerosis …, 2014 - journals.sagepub.com
Background: Several studies have shown that pregnancy reduces multiple sclerosis (MS)
relapses, which increase in the early postpartum period. Postpartum relapse risk has been …
relapses, which increase in the early postpartum period. Postpartum relapse risk has been …
Defining secondary progressive multiple sclerosis
J Lorscheider, K Buzzard, V Jokubaitis, T Spelman… - Brain, 2016 - academic.oup.com
A number of studies have been conducted with the onset of secondary progressive multiple
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …
sclerosis as an inclusion criterion or an outcome of interest. However, a standardized …
Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis
Background and Objectives People with multiple sclerosis (MS) are a vulnerable group for
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …
severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive …